Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: Eleven new cases and a review of 51 previously published cases

Journal of Neuro-Ophthalmology

Volumn 21, Issue 3, 2001, Pages 173-187

  Keltner, John L ^a,b   Thirkill, Charles E ^a   Yip, Peter T ^a  

^a Department of Ophthalmology ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretinal antibodies; Immunology; Intravenous immunoglobulin treatment; Melanoma associated retinopathy; Photopsia

Indexed keywords

ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RETINA ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONVALESCENCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; MELANOMA; MELANOMA ASSOCIATED RETINOPATHY; METASTASIS; PRIORITY JOURNAL; RETINA BIPOLAR GANGLION CELL; RETINOPATHY; SYMPTOM; SYNDROME; UNITED STATES; VISUAL ACUITY;

EID: 0034748752     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200109000-00004     Document Type: Article

References (86)

1. Paraneoplastic diseases of neuro-ophthalmology interest
2. Blindness caused by photoreceptor degeneration as a remote effect of cancer
3. Photoreceptor degeneration. Possible autoimmune disorder
4. Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome
5. Cancer-associated retinopathy
6. Autoimmune basis for visual paraneoplastic syndrome in patients with small cell lung carcinoma. Retinal immune deposits and ablation of retinal ganglion cells
7. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells [see comments]
8. The cancer-associated retinopathy antigen is a recoverin-like protein
9. Management and monitoring of cancer-associated retinopathy
10. Acute Vogt-Koyanagi-Harada-like syndrome occurring in a patient with metastatic cutaneous melanoma
11. Functional abnormalities in vincristine-induced night blindness
12. Inner retinal layer loss in complicated migraine. Case report
13. Paraneoplastic night blindness with malignant melanoma
14. 'On' response defect in paraneoplastic night blindness with cutaneous malignant melanoma
15. S-cone and rod ERGs reduced in paraneoplastic retinal degeneration
16. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy
17. Paraneoplastic retinopathy in malignant melanoma
18. Full-field electroretinogram in a patient with cutaneous melanoma-associated retinopathy
19. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma
20. Clinical aspects: Paraneoplastic retinopathy
21. Cutaneous melanomaassociated retinopathy
22. An unusual case of melanoma-associated retinopathy
23. Severe course of cutaneous melanoma associated paraneoplastic retinopathy
24. Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case
25. Melanoma-associated retinopathy. Apropos of a case and review of the literature
26. Cutaneous melanoma-associated retinopathy with retinal periphlebitis
27. Melanoma-associated retinopathy
28. Selective magnocellular damage in melanoma-associated retinopathy: Comparison with congenital stationary nightblindness
29. Paraneoplastic retinopathy associated with metastatic cutaneous melanoma of unknown primary site
30. Melanoma-associated paraneoplastic retinopathy: Case report and review of the literature
31. Melanoma-associated retinopathy with night blindness. Case report
32. Cutaneous melanoma-associated paraneoplastic retinopathy: Histopathologic observations
33. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy
34. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo
35. Node way out
36. Melanoma-associated retinopathy versus abnormal retinal function due to interferon-alpha/isotretinoin therapy in cutaneous malignant melanoma
37. Antiretinal Muller cell antibodies in patients with melanoma associated and autoimmune retinopathy
38. Electrophysiological features of melanoma associated retinopathy (MAR)
39. Ocular findings in 28 patients with cutaneous malignant melanoma (CMM)
40. Autoimmune retinopathy in the absence of cancer
41. Muller cell-specific autoantibodies in a patient with progressive loss of vision
42. Recoverin-associated retinopathy: A clinically and immunologically distinctive disease
43. The 22-kDa antigen in optic nerve and retinal diseases
44. Autoimmune retinopathy: Patients with antirecoverin immunoreactivity and panretinal degeneration
45. Cancer-associated retinopathy vs recoverin-associated retinopathy
46. Retinal pigment epithelial hypersensitivity, an association with vision loss: RPE hypersensitivity complicating paraneoplastic retinopathies
47. Retinitis pigmentosa misdiagnosed as complicated migraine. In reply
48. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade
49. Antiretinal bipolar cell antibodies of melanoma-associated retinopathy in the absence of melanoma
50. Molecular mimicry and autoimmunity
51. A retinal bipolar cell protein is recognized by autoantibodies from patients with melanoma-associated retinopathy [abstract]
52. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma
53. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: Report of 3 cases
54. The use of intravenous immunoglobulin for neurologic diseases
55. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis
56. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange
57. Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebocontrolled study
58. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: A preliminary study
59. The treatment of refractory uveitis with intravenous immunoglobulin
60. Linear IgA bullous disease limited to the eye: A diagnostic dilemma: Response to intravenous immunoglobulin therapy
61. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases
62. Gamma-globulin inhibits tumor spread in mice
63. Prophylactic immune globulin in chronic lymphocytic leukemia
64. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment of polymyositis
65. Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma
66. Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression
67. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response
68. Suppressive immunoregulatory factors produced by tumors
69. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
70. Demonstration of lymphocyte blastogenesis-inhibiting factors in sera of melanoma patients
71. Antigens and antibodies in malignant melanoma
72. Therapeutic apheresis in neurologic disorders
73. A review of the therapy of paraneoplastic neurologic syndromes
74. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. A case report
75. Management of neurologic disorders
76. Paraneoplastic retinopathy
77. A clinical triad to diagnose paraneoplastic retinopathy
78. Long-term persistence of antirecoverin antibodies in endometrial cancer-associated retinopathy [letter]
79. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
80. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma
81. Dendritic cell vaccines for cancer immunotherapy
82. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]
83. Immune and gene therapy for melanoma, and the immunobiology of melanoma
84. Cancer gene and immunotherapy: Recent developments
85. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
86. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma